Tisotumab vedotin | Interleukin Related interleukin-related.com

Product Name :
Tisotumab vedotin

Search keywords :
Val-Cit

drugId :
null

Target Vo:
Tissue factor

Target Vo Short Name :
TF

Moa_Name:
Tubulin polymerisation inhibitors

First Approval Country :
United States

First Approval Date Filter:
2021

Origin Company_Name :
Genmab A/S

Active Company_Name :
Baxter Oncology Gmbh

Active Indication_Name:
Uterine Cervical Neoplasms

In Active Indication_Name:
Urinary Bladder Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
RhoA Rabbit pAb In stock
Ladiratuzumab Autophagy
PRDX3 Antibody (YA909): PRDX3 Antibody (YA909) is an unconjugated, approximately 28 kDa, human-derived, anti-PRDX3 (YA909) monoclonal antibody. PRDX3 Antibody (YA909) can be used for: WB, IF-Cell, IHC-P, FC, IP expriments in human background without labeling.

Author: Interleukin Related

Related Posts